{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T23:52:51Z","timestamp":1787356371750,"version":"build-2736575974"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,6,15]],"date-time":"2023-06-15T00:00:00Z","timestamp":1686787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2023,6,15]]},"abstract":"<jats:p>Tebipenem pivoxil hydrobromide (TBP-PI-HBr) is an oral (PO) carbapenem pro-drug that is converted to the active moiety tebipenem in the enterocytes. Tebipenem has activity against multidrug-resistant Gram-negative pathogens, including extended-spectrum beta lactamase-producing Enterobacterales, and is being developed for the treatment of patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP).<\/jats:p>","DOI":"10.1128\/aac.01451-22","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T14:10:20Z","timestamp":1684246220000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":7,"title":["Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide"],"prefix":"10.1128","volume":"67","author":[{"given":"H.","family":"Ganesan","sequence":"first","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8093-5126","authenticated-orcid":true,"given":"V. K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0452-682X","authenticated-orcid":true,"given":"M. C.","family":"Safir","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-6467","authenticated-orcid":true,"given":"S. M.","family":"Bhavnani","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. K.","family":"Talley","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-6361","authenticated-orcid":true,"given":"D.","family":"Melnick","sequence":"additional","affiliation":[{"name":"Spero Therapeutics, Inc., Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3172-0847","authenticated-orcid":true,"given":"C. M.","family":"Rubino","sequence":"additional","affiliation":[{"name":"Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/14787210.2018.1496821"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02618-18"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00618-19"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02407-21"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00145-21"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105462"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13280"},{"key":"e_1_3_3_10_2","doi-asserted-by":"crossref","unstructured":"VanScoy BD Onufrak NJ Conde H Bhavnani SM Cotroneo N Critchley IA Parr TR Ambrose PG. Characterization of tebipenem pharmacokinetics-pharmacodynamics for efficacy against Enterobacteriaceae in a one-compartment in vitro infection model. IDWeek 2019. October 1\u20136 2019; Washington DC poster 1565.","DOI":"10.1093\/ofid\/ofz360.1429"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-130-6-199903160-00002"},{"key":"e_1_3_3_12_2","unstructured":"Srivastava P Manyak E Utley L Gupta V. A validated sensitive and selective ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS\/MS) method for quantitative analysis of tebipenem pivoxil and tebipenem in human whole blood and its application in a pharmacokinetic study in healthy volunteers. Poster presented at 15 th WRIB Virtual Meeting. September 27 \u2013 October 1 2021."},{"key":"e_1_3_3_13_2","volume-title":"NONMEM users guides; introduction to NONMEM 7.4.1.","author":"Bauer RJ","year":"2017","unstructured":"Bauer RJ. 2017. NONMEM users guides; introduction to NONMEM 7.4.1. ICON Plc, Gaithersburg, MD."},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9255-z"},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","unstructured":"Baron KT. 2017. mrgsolve: simulate from ODE-Based Population PK\/PD and Systems Pharmacology Models. R package Version 0.8.6.","DOI":"10.32614\/CRAN.package.mrgsolve"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1201\/b14095"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01451-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/aac.01451-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,20]],"date-time":"2024-10-20T13:36:21Z","timestamp":1729431381000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/aac.01451-22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6,15]]}},"alternative-id":["10.1128\/aac.01451-22"],"URL":"https:\/\/doi.org\/10.1128\/aac.01451-22","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]},"assertion":[{"value":"2022-11-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01451-22"}}